A Study of CS1002 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.
Solid Tumor, Adult
DRUG: CS1002|DRUG: CS1003
Number of participants with adverse events, From the day of first dose to 30 days after last dose of CS1002
This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.